Clinical Trial Update: Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm [Phase 2]

View source ↗

Summary

Phase 2 study evaluating a single administration of 3 doses of Dysport for benign essential blepharospasm has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Blepharospasm

Drugs mentioned

• Dysport (abobotulinumtoxinA)

Snippet

Sponsor: Ipsen | Conditions: Blepharospasm | Phase 2 | Status: COMPLETED